shadow_tr

Welcome

Education

Research

Clinical Services

Personnel

Conferences

Annual Lectureships

News


Tulane University Health Sciences
Department of Pathology and Laboratory Medicine
1430 Tulane Avenue SL-79
New Orleans, Louisiana
70112-2699
Phone 504-988-5224
Fax 504-988-7389
Email tulpath@tulane.edu

Shanker Japa, MPhil, PhD

Shanker Japa, M.Phil., Ph.D.

 

RESEARCH ASSOCIATE PROFESSOR


RESIDENCY:

Res. Fellow. Training in Clinical Chemistry/Molecular Diagnostics,
                      Tulane University Hospital and Clinic, New Orleans, LA, (1995-2000).

 

EDUCATION:

Ph.D.        School of Environmental Sciences, Jawaharlal Nehru University,
                  New Delhi, India, 1985.
M. Phil.     School of Environmental Sciences, Jawaharlal Nehru University,
                  New Delhi, India, 1981.
M.S.          Zoology/Cell Physiology, Kakathiya University, Warangal, India, 1978.

B.S.
          Botany, Zoology and Chemistry, Osmania University, Hyderabad, India,1976.

 

CERTIFICATIONS:

·       Board eligible for the Diploma in American Board of Clinical Chemistry and Molecular Diagnostics.
·      
TRUGENE HIV Genotyping Assay using the OpenGene DNA Sequencing System.   

 

MAJOR AREAS OF RESEARCH INTEREST:

·       Human Retroviruses (HIV, HTLV-I, HTLV-II).
·      
Molecular diagnostics of Infectious Diseases.
·      
HIV Genotypic Drug Susceptibility Testing.
·      
Multidrug resistance mechanisms in Infectious Diseases and cancer.

 

CONFERENCE/MEETING ABSTRACTS:

  • AACR annual  meeting, Washington DC. April 1-5, 2006.

  • Dreisbach AW, Japa S, Gebrekal AB, Fonseca JP, Parenti M, Lertora JJL. Prevalence of CYP2C8 polymorphisms in African-Americans on hemodialysis. Clin Pharmacol Ther 2004.

  • Dreisbach AW, Japa S, Gebrekal AB, Lertora JJL.Prevalence of Cytochrome P450 CYP2C9 Polymorphisms in African-Americans on Hemodialysis. J Am Soc Nephrol. (Abstract).

  • Dreisbach AW, Japa S, Kamath B, Mowry SE, Gebrekal A, Tenaglia AN, Lertora JJL.Endstage Renal Disease (ESRD) Reduces Hepatic CYP2C9 Activity as Measured by Plasma S/R Warfarin Ratio. Clin Pharmacol Ther 71(2):P9, 2002 (Abstract).

SELECTED RECENT PEER-REVIEWED PUBLICATIONS:

1.     Dreisbach AW, Rice, JC, Japa, S, Newman JW, Sigel A, Gill  RS, Hess AE, Cemo, AC, Fonseca, JP, Hammock, Lertora JL, and Hamm LL. Salt Loading Increases Urinary Excretion of Linoleic Acid Diols and Triols in Healthy Human Subjects. Hypertension. 2008; 51:755

2.     Chuang CZ, Boyles A, Legardeur B, Su J, Japa S, Lopez-S A.Effects of riboflavin and folic acid supplementation on plasma homocysteine levels in healthy subjects. Am J Med Sci. 2006; 331: 65-71.

3.     Dreisbach AW, Japa S, Sigel A, Parenti MB, Hess AE, Srinouanprachanh SL, Rettie AE, Kim H, Farin FM, Hamm LL, Lertora JJ. The Prevalence of CYP2C8, 2C9, 2J2, and Soluble Epoxide Hydrolase Polymorphisms in African Americans With Hypertension. Am J Hypertens. 2005; 18: 1276-81.

4.     Beilke MA, Japa S, Moeller-Hadi C, Martin-Schild S.Tropical spastic paraparesis/human T leukemia virus type 1-associated myelopathy in HIV type1-coinfected patients. Clin Infect Dis. 2005; 15: 57-63.

5.     Clejan S. Japa S., Gebrekal A., Vidulescu C. and Seltzer B (2004). Immune responses induced by intranasal imiquimod and implications for therapeutics in rhinovirus infections. J Cell Mol Med. 2005; 9: 457-61.

6.     Dreisbach AW, Japa S, Gebrekal AB, Mowry  SE, Kamath BL, Rettie, AE, and  Lertora JJL (2003) Cytochrome P4502C9 activity in end-stage renal disease. Clin. Pharmacol. Ther. 73 (5), 475-477.

7.     Dreisbach AW, Japa S, Kamath BL, Mowry SE, Gebrekal A, Tanaglia AN, Lertora JJL. Endstage renal disease (ESRD) reduces hepatic cytochrome P450 CYP2C9 activity.  J Invest Med 50: 141A, 2002.

 

Dept. of Pathology & Laboratory Medicine, 1430 Tulane Avenue, New Orleans, LA 70112 504-988-5224 tulpath@tulane.edu